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Abstract 
Objective: In early axial spondyloarthritis (axSpA) data is lacking about the relationship 
between disease activity and health-related quality of life (HRQoL). In early axSpA, we 
assessed and quantified the association between change in Ankylosing Spondylitis Disease 
Activity Score (ASDAS) and HRQoL over time. 
Methods: Baseline and one-year data of axSpA patients fulfilling the ASAS classification 
criteria from the SPACE-cohort were analyzed. Associations between change in ASDAS and 
in physical (PCS) or mental component summary (MCS) of the 36-item Short Form (SF-36) 
were tested by linear regression models. Age, gender, ASAS criteria arm, and blue- vs. 
white-collar work were tested for effect modification. Subsequently, these factors and 
medication were tested for confounding.  
Results: 161 axSpA patients (53% male, mean (SD) age 29.7 (7.5) years, mean symptom 
duration 13.6 (7.2) months, HLA-B27+ 91%, radiographic sacroiliitis 22%) had a mean (SD) 
ASDAS of 2.5 (1.0) and 2.0 (0.8), PCS of 28.4 (14.3) and 36.9 (13.1), and MCS of 48.2 (13.8) 
and 49.3 (12.0) at baseline and one year, respectively. Per unit increase in ASDAS between 
baseline and one year, PCS worsened by 9.5 points. The same level of disease activity had 
less adverse impact on physical HRQoL in women and white-collar workers.  
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Conclusion: Our data are the first to show that in a broad group of patients with early axSpA 
increasing ASDAS is associated with worsening in physical HRQoL, but not mental HRQoL, 
over time.  
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A task force of international experts recently published recommendations for treat to target 
(T2T) in axial spondyloarthritis (axSpA) and formulated the primary goal of T2T being to 
maximize long-term health-related quality of life (HRQoL) and social participation. In order 
to achieve these outcomes, the proposed treatment target is inactive disease or, 
alternatively, low disease activity by Ankylosing Spondylitis Disease Activity Score (ASDAS) 
(1).  
 It is well-known that ankylosing spondylitis (AS, radiographic axSpA) has a substantial 
impact on HRQoL and that increased disease activity influences HRQoL adversely (2-4). 
Similar data of patients with early axSpA is lacking. 
 Data from patients with AS cannot be extrapolated to patients with early axSpA. For 
instance, most patients with early axSpA do not have radiographic sacroiliitis and gender 
distribution is similar, while patients with severe AS are more often male (5, 6).  
 But also in early axSpA patients changes in disease activity over time seem to be 
associated with changes in HRQoL. In the ABILITY-1 trial in patients with non-radiographic 
axSpA an improvement in disease activity as measured by the ASDAS was associated with an 
improvement in HRQoL (7). However, patients in the ABILITY-1 trial had a relatively long 
symptom duration (8-10 years), had exclusively non-radiographic axSpA, and a high level of 
disease activity necessitating treatment with a tumor necrosis factor (TNF)-inhibitor.  
 It is rational to assume that the association between changes in disease activity and 
changes in HRQoL found in AS also extends to patients with early axSpA. However, it is 
unclear if this association is of similar magnitude in relevant subgroups of axSpA. The 
association may, for instance, be different in males and females, or in those with sedentary 
jobs vs. physically demanding ones. For example, physically demanding jobs are associated 
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with greater functional limitations in AS patients and have been reported to have a negative 
impact on HRQoL (8, 9). Further, women have a higher disease activity and worse physical 
functioning compared to men (10). 
 In order to implement T2T strategies in patients with early axSpA, more information 
is needed about the association between disease activity and HRQoL in these patients and 
relevant subgroups in daily clinical practice. Therefore, the objective of this study was to 
assess and quantify the association between the change in disease activity and in HRQoL in 
a broad patient population with early axSpA and in relevant subgroups over time.  
 
Materials and Methods 
Baseline and one-year data from the SPondyloArthritis Caught Early (SPACE) cohort, which 
has been described in detail previously (5), were analyzed. In brief, the SPACE cohort is an 
ongoing inception cohort that includes patients above 16 years of age with chronic back 
pain (CBP; persisting ≥3 months and ≤2 years, and onset <45 years). For the current study, 
the database was locked on March 31 2017. Patients were recruited from multiple European 
sites in the Netherlands, Norway, Italy, and Sweden. The SPACE cohort has been approved 
by the medical ethical committee of the Leiden University Medical Center (LUMC, P08.105). 
Informed consent forms from all study participants had been obtained beforehand. 
 
All study participants underwent a full work-up as part of the study protocol at baseline and 
one year consisting of medical history, physical examination, laboratory assessments (C-
Reactive Protein (CRP), erythrocyte sedimentation rate (ESR)), and questionnaires. At 
baseline, human leukocyte antigen (HLA)-B27 was tested, and magnetic resonance imaging 
(MRI) and radiography of the sacroiliac joints and spine were obtained. The treating 
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rheumatologist provided the diagnosis using local reading of imaging and indicated the level 
of confidence regarding the diagnosis on a numerical scale (0, not confident at all; 10, very 
confident). For classification, central reading was performed by three readers per imaging 
modality. Images were considered to be positive for sacroiliitis when ≥2 readers agreed 
using the modified New York criteria (mNY) for radiographs (11) and Assessment of 
Spondyloarthritis international Society (ASAS) definition for a positive MRI of the sacroiliac 
joints (12). Patients diagnosed with axSpA were classified according to the ASAS axSpA 
criteria (13) to the clinical arm (HLA-B27 + 2 SpA features) if patients fulfilled the clinical arm 
exclusively and to the imaging arm (sacroiliitis + 1 SpA feature) if patients fulfilled either the 
imaging arm alone or both arms.  
 
Disease activity had been assessed by the ASDAS (CRP based) (14, 15). The level of disease 
activity was categorized as inactive disease (ASDAS <1.3), moderate disease activity (ASDAS 
<2.1), high disease activity (ASDAS ≤3.5), and very high disease activity (ASDAS >3.5) (16). 
 
HRQoL was assessed by the 36-item Short-Form Health Survey (SF-36) (17). Eight subscales 
were calculated and transformed into scale scores with numeric scales ranging from 0 
(worst health) to 100 (best health) after recoding and recalibration. These scale scores were 
weighted according to gender, age, and country (18, 19). As no Italian age- and gender-
matched scores were available, Dutch age- and gender-matched scores were used for all 
Italian patients (n=26). The adjusted scores were used to calculate two summary measures, 
the physical (PCS) and mental component summary (MSC). In rare cases (n=6) of a negative 
PCS scores were set to zero. The PCS and MCS were transformed in order to compare the 




The patient’s job-type was determined using a multiple-choice question with the following 
options;  
1. Management position (e.g. director, manager, member of the board of directors),  
2. Professional specialist (engineer, teacher, nurse practitioner, systems analyst),  
3. Commercial profession (representative, agent, clerk, sales person),  
4. Technical support (lab technician, legal officer, IT),  
5. Administrative support (secretary, invoice administration),  
6. Service profession (security officer, janitor), and  
7. Operator or labourer (assembler, mechanic, carpenter, builder). Answer options 1, 2, 3, 4, 
and 5 were considered to reflect ‘white-collar workers’ and answer options 6 and 7 were 
considered to reflect ‘blue-collar workers’. 
 
The use of non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic disease-
modifying antirheumatic drugs (csDMARDs), and biological DMARDs (bDMARDs) were each 
separately categorized as ‘no medication’, ‘stopped using medication’, ‘started using 
medication’, and ‘continued use of medication’ between baseline and one year. Twelve 
patients were already treated with csDMARDs and one patient with bDMARDs at baseline 
because of inflammatory bowel disease, uveitis, dactylitis, peripheral arthritis, psoriasis, or a 
combination thereof.  
 
Analysis 
Patients diagnosed with axSpA and fulfilling the ASAS classification were included in the 
analysis. Categorical variables were described as frequencies (proportions) and continuous 
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variables as means and standard deviations (SD). Linear regression models were built with 
∆ASDAS as independent variable and ∆PCS or ∆MCS as dependent variable between 
baseline and one year. Age at baseline, gender, ASAS axSpA subclassification (imaging vs. 
clinical arm), and job-type (white-collar vs. blue-collar) at baseline were tested for effect 
modification one by one in each model and stratification of the models was conducted if 
effect modification was found (p-value for the interaction term <0.10). To prevent spurious 
effects due to small sample sizes, stratification was only performed if each subgroup 
consisted of at least 15 patients. Subsequently, these factors and in addition treatment 
were tested for confounding (crude regression coefficient changed by >10% after adding 
each factor) and models were adjusted for each confounder. Data were analysed using 
STATA SE V.14 (Statacorp, College Station, Texas, USA). P-values of <0.05 were considered to 
be statistically significant. 
 
Results 
In total, 361 patients had baseline and one-year data. Of the 361 patients, 107 did not have 
an axSpA diagnosis, the diagnosis was missing (n=7), or did not fulfill the classification 
criteria after diagnosis (n=73). The ASDAS could not be calculated in 12 patients and 1 
patient did not fill out the SF-36.  
 
Of the 161 patients with axSpA, 53% was male, mean (SD) age was of 29.7 (7.5) years, and 
mean symptom duration was 13.6 (7.2) months (Table 1). Patients had on average 5 SpA 
features, including imaging and HLA-B27 carriership. Mean level of confidence in diagnosis 
was 8 (SD 2). Patients had a mean (SD) ASDAS of 2.5 (1.0) at baseline and 2.0 (0.8) at one 
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year. At baseline, 11% of the patients had inactive disease, 27% moderate disease activity, 
48% high disease activity, and 14% very high disease activity (Table 2).  
 
The mean (SD) PCS was 28.4 (14.3) at baseline and increased to 36.9 (13.1) at one year 
(Table 2). The MCS remained constant between baseline and one year (mean (SD) 48.2 
(13.8) at baseline, 49.3 (12.0) at one year) and was comparable to the general population 
(MCS=50). No correlation was found between the change in ASDAS and the change in MCS 
(r=-0.05, p=0.54). Therefore, the regression analyses focused on PCS only.  
 
Between baseline and one year, one unit change in ASDAS (∆ASDAS) led on average to 9.5 
points change in PCS (∆PCS, Figure 1). The SF-36 subscales role physical, bodily pain, and 
physical functioning changed the most compared to other subscales between baseline and 
one year per unit change of the ASDAS (see Table 3, β=-24.5, 95%CI -30.1; -18.8, β=-17.2, 
95%CI -19.9; -14.5, and β=-12.6, 95%CI -15.2;-10.1, respectively).  
 
The association between ∆ASDAS and ∆PCS was modified by gender (p=0.056 for the 
interaction term) and job-type (p=0.077, Table 4). Information about profession was 
provided by 79 patients out of 129 patients who worked at baseline (61.2%). The association 
between ∆ASDAS and ∆PCS was less strong in women (β=-7.7, 95%CI -9.9; -5.5) than in men 
(β=-11.0, 95%CI -13.7; -8.4) and in white-collar workers (β=-9.6, 95%CI -12.3; -7.0) than in 
blue-collar workers (β=-15.6, 95%CI -23.0; -8.3). No effect modification or confounding was 
found by age or ASAS classification arm (clinical or imaging arm). Also, no confounding by 




In 102 out of 161 patients, two-year data were also available. Similar results were found for 
ASDAS, PCS, and MCS at both baseline and one year for these patients as compared to 
patients with one year data only. Over two years ASDAS (1.9 (SD 0.9)) and PCS (39.1 (SD 
12.2)) improved slightly and MCS remained stable (50.1 (SD 11.2)). Most importantly, the 
association between ∆ASDAS and ∆PCS was similar between baseline and one-year (β=-9.8, 
95%CI -12.2;-7.5), and one-year and two-year follow-up (β=-8.9, 95%CI -11.1;-6.7). 
 
Discussion 
Compared to the general population, patients with early axSpA are limited in physical 
HRQoL, but not in mental HRQoL. Furthermore, our data indeed confirm that in a broad 
group of patients with early axSpA in clinical care an increase in disease activity is associated 
with a decline in physical HRQoL over time. Moreover, to our knowledge, we have 
quantified for the first time the association between ASDAS and HRQoL. Our results confirm 
the hypothesis used for treat-to-target that it is important to aim for lower disease activity 
in early axSpA patients in order to improve HRQoL.  
 
The most important finding of this study is that the strength of the association between 
disease activity and HRQoL is gender-specific and job-type-specific. Knowledge is limited 
regarding the association in these subgroups of patients. A similar level of disease activity 
seems to impact HRQoL more adversely in men than in women. A possible explanation for 
this difference is that men and women appear to cope differently with the disease (21, 22). 
In addition, the differences for job-type could also be explained by gender. A similar 
proportion of males and females had a white-collar job (49% vs. 51%, respectively). But 61% 
of blue-collar workers was male. Unfortunately, no separate effects for subgroups stratified 
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on both gender and job-type could be evaluated due to the small patient number in these 
subgroups. It is possible that physical HRQoL is more important for blue-collar workers than 
for white-collar workers, because good physical HRQoL enables them to do their work. Our 
results show that a similar improvement in disease activity is associated with more 
improvement in HRQoL in blue-collar workers than in white-collar workers. Thus, blue-collar 
workers may benefit more from decreasing disease activity. However, the observed 
difference between blue- and white-collar workers should be interpreted with caution as 
only 61.2% of all working patients provided information about their job-type. Consequently, 
these associations require further study.  
 
The association found between disease activity and HRQoL may not be a surprising 
correlation as both ASDAS and SF-36 do contain several questions that appear similar. For 
instance the ASDAS includes spinal and peripheral pain questions and the SF-36 contains 
questions about bodily pain. However, the ASDAS is a disease-specific composite score 
developed and validated for axSpA and also contains CRP. The SF-36 is a generic 
questionnaire aimed at measuring HRQoL and includes measurements of role emotional and 
social functioning.  
 
A strength of this study is the high diagnostic certainty of axSpA after a thorough diagnostic 
work-up in all patients. In addition, the mean values of ASDAS (baseline 2.5, one year 2.0) 
and PCS (baseline 28.4, one year 36.9) in our cohort are comparable to other axSpA cohorts. 
For example, in the Devenir des Spondyloarthrites Indifférenciées Récentes (DESIR) cohort, 
early axSpA patients (symptom duration <3 years) had a mean ASDAS of 2.6 and PCS of 41 
(23) and in the Herne (24) and Swiss Clinical Quality Management (SCQM) cohorts (25) (non-
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radiographic axSpA with a symptom duration >5 years) the mean ASDAS ranged from 2.8 to 
3.0 and PCS from 20 to 42, respectively. The ESPERANZA cohort has also found an 
association between the bath ankylosing spondylitis disease activity index (BASDAI) and the 
ankylosing spondylitis quality of life (ASQoL) questionnaire. As two different outcome 
measurements were used, no direct comparisons between this cohort and the SPACE cohort 
were possible (26). 
 
In summary, mental functioning of patients with early axSpA is comparable to the general 
population. However, even in the earliest phase of disease, axSpA patients are already 
impaired in their physical HRQoL. Moreover, for the first time we show that in a broad 
group of patients with early axSpA increasing disease activity is associated with worsening in 
physical HRQOL over time. This finding supports the recommendation that also in early 
axSpA patients inactive disease or low disease activity should be the treatment target. 
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Figure 1: Scatterplot of the correlation between change in ASDAS (∆ASDAS) and change in 
PCS (∆PCS) between baseline and one year with the disease state at baseline indicated. 
 
 
 
 
